

## Regimen Reference Order – MULTI – CARBOplatin + etoposide

ARIA: MULTI - [CARBOplatin + etoposide]

Planned Course: Every 21 days for 4 to 6 cycles

Indication for Use: Small Cell Carcinoma

CVAD: At Provider's Discretion

### Proceed with treatment if:

ANC equal to or greater than  $1.5 \times 10^9/L$  AND Platelets equal to or greater than  $100 \times 10^9/L$

❖ Contact Physician if parameters not met

## SEQUENCE OF MEDICATION ADMINISTRATION

### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

### Treatment Regimen – MULTI – CARBOplatin + etoposide

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
<b>Day 1</b>		
aprepitant	125 mg	Orally 1 hour pre-chemotherapy
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy
CARBOplatin	AUC 6 mg/mL.min; maximum dose 900 mg (see table below)	IV in D5W 250 mL over 30 minutes
etoposide	75 mg/m <sup>2</sup>	IV in normal saline 500 mL over 1 hour <i>Use non-DEHP bags and non-DEHP administration sets</i>
<b>Days 2 and 3</b>		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
etoposide	75 mg/m <sup>2</sup>	IV in normal saline 500 mL over 1 hour <i>Use non-DEHP bags and non-DEHP administration sets</i>

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

## REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin and albumin as per Physician Orders

Recommended Support Medications		
Drug	Dose	CCMB Administration Guideline
aprepitant	80 mg	Orally once daily on Days 2 and 3
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

**DISCHARGE INSTRUCTIONS**

- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

**ADDITIONAL INFORMATION**

- Patients with limited stage disease (Stages I-III) typically receive 4 cycles of treatment, while patients with extensive stage disease (Stage IV) may receive 4 to 6 cycles
- ARIA regimen is built as 4 cycles. Treatment may be extended to 6 cycles for some patients at the discretion of the oncologist
- CARBOplatin dose considerations:
  - CCMB uses **actual body weight** to calculate GFR
  - CCMB uses a maximum CARBOplatin dose of 900 mg for this regimen
  - If calculated CARBOplatin dose differs **more than 10%** from prescribed CARBOplatin dose, contact the prescriber

**CARBOplatin Dosing Calculations per CCMB**  
*Calculation of CARBOplatin dose: (maximum 900 mg)*

Dose (mg) = target AUC (GFR + 25)

$$\text{GFR} = \frac{N \times (140 - \text{age in years}) \times \text{Actual Body Weight (kg)}}{\text{serum creatinine in micromol/L}} = \text{___ mL/min}$$

N = 1.23 in males  
 N = 1.04 in females

AUC (mg/mL.min) <hr style="width: 50%; margin: 0 auto;"/> 6	X	GFR + 25 (mL/min) <hr style="width: 50%; margin: 0 auto;"/> ___ + 25	=	Total Dose (mg) <hr style="width: 50%; margin: 0 auto;"/>
---	---	--	---	---

AUC = Area Under Curve

*The estimated creatinine clearance is based on limited evidence. Sound clinical judgment and interpretation of the estimation are required, because the equation above may not be appropriate for some patient populations (for example, acute renal failure).*